Inflarx NV (NASDAQ:IFRX) has received an average rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $53.13.
Several equities research analysts recently weighed in on IFRX shares. Robert W. Baird assumed coverage on shares of Inflarx in a report on Monday, January 28th. They issued an “outperform” rating and a $62.00 price objective for the company. Credit Suisse Group assumed coverage on shares of Inflarx in a report on Monday, December 10th. They issued an “outperform” rating and a $47.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Inflarx from $42.00 to $65.00 and gave the company a “top pick” rating in a report on Tuesday, February 5th. ValuEngine raised shares of Inflarx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, Guggenheim assumed coverage on shares of Inflarx in a report on Friday, February 22nd. They issued a “buy” rating and a $65.00 price target for the company.
IFRX stock opened at $43.01 on Friday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -14.63 and a beta of -0.84. Inflarx has a fifty-two week low of $20.31 and a fifty-two week high of $51.33.
Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Inflarx in the 3rd quarter valued at about $277,000. Jane Street Group LLC acquired a new stake in Inflarx during the 3rd quarter worth about $278,000. JPMorgan Chase & Co. raised its holdings in Inflarx by 29.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock worth $367,000 after buying an additional 2,420 shares during the period. Northern Trust Corp raised its holdings in Inflarx by 46.9% during the 2nd quarter. Northern Trust Corp now owns 11,624 shares of the company’s stock worth $375,000 after buying an additional 3,709 shares during the period. Finally, Paloma Partners Management Co acquired a new stake in Inflarx during the 4th quarter worth about $526,000. 56.56% of the stock is owned by institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Read More: How do investors use RSI to grade stocks?
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.